As the S&P/ASX 200 reflects global market jitters with a predicted dip following Wall Street's inflation concerns, investors are keenly watching for opportunities in growth companies that demonstrate resilience and potential. In this environment, stocks with high insider ownership can be particularly appealing as they often signal confidence from those who know the company best, aligning management interests with shareholder value.
| Name | Insider Ownership | Earnings Growth |
| Wisr (ASX:WZR) | 10.2% | 94.2% |
| Titomic (ASX:TTT) | 14.7% | 71.3% |
| Starpharma Holdings (ASX:SPL) | 19.3% | 92% |
| SKS Technologies Group (ASX:SKS) | 19.3% | 27.7% |
| PDI Gold (ASX:PDI) | 10.4% | 63.6% |
| Forrestania Resources (ASX:FRS) | 32.3% | 126.7% |
| Echo IQ (ASX:EIQ) | 17.6% | 69.1% |
| Austral Resources Australia (ASX:AR1) | 22.9% | 28.2% |
| Auric Mining (ASX:AWJ) | 19.7% | 38.6% |
| Advanced Engineered Materials (ASX:AEM) | 35.1% | 52.2% |
Let's uncover some gems from our specialized screener.
Simply Wall St Growth Rating: ★★★★★★
Overview: Echo IQ Limited provides artificial intelligence diagnostics tools to improve the diagnosis of structural heart disease in Australia and has a market cap of A$1.05 billion.
Operations: The company's revenue is derived from the development of AI software, amounting to A$0.09 million.
Insider Ownership: 17.6%
Earnings Growth Forecast: 69.1% p.a.
Echo IQ is poised for significant growth, with revenue expected to increase by 73.9% annually, outpacing the broader Australian market. Despite current low revenues of A$91K and a net loss of A$18.57 million, analysts predict profitability within three years and a potential stock price rise of 25.4%. Recent strategic moves include a collaboration with Mayo Clinic to enhance its AI platform's applicability in oncology and an executive appointment aimed at strengthening its US market presence.
Simply Wall St Growth Rating: ★★★★★★
Overview: Mesoblast Limited, along with its subsidiaries, focuses on developing regenerative medicine products in Australia and has a market capitalization of A$3.06 billion.
Operations: The company generates revenue of $120.25 million from the development and commercialization of its allogeneic cellular medicines platform.
Insider Ownership: 33.6%
Earnings Growth Forecast: 51.3% p.a.
Mesoblast's growth prospects are strong, with revenue forecasted to grow at 36.7% annually, significantly outpacing the Australian market. The company reported a substantial increase in revenue to US$120.25 million for FY2026, while reducing its net loss from US$102.14 million to US$57.5 million year-over-year. With high insider ownership and strategic advancements in regenerative medicine, Mesoblast is expected to achieve profitability within three years and has promising potential in addressing chronic low back pain through its Phase 3 trial of rexlemestrocel-L.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Pinnacle Investment Management Group Limited is an Australian investment management company with a market cap of A$3.93 billion.
Operations: The company generates revenue from its Funds Management Operations, totaling A$109.69 million.
Insider Ownership: 24.4%
Earnings Growth Forecast: 13.4% p.a.
Pinnacle Investment Management Group demonstrates growth potential with a recent 31.5% earnings increase and revenue rising to A$109.69 million for FY2026, up from A$65.48 million the previous year. Insider ownership remains high, with minimal insider selling over the past three months, suggesting confidence in its trajectory. Despite an unstable dividend track record, Pinnacle's earnings are forecasted to grow at 13.4% annually, outpacing the Australian market's average growth rate of 11.3%.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com